BeOne Medicines (ONC) Return on Capital Employed (2016 - 2026)

BeOne Medicines (ONC) has 11 years of Return on Capital Employed data on file, last reported at 10.46% in Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 1805.0% year-over-year to 10.46% in Q1 2026; TTM through Mar 2026 was 10.46%, a 1805.0% increase from a year earlier, with the FY2025 full-year figure at 8.56%, up 2413.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 10.46%, up from 7.35% in the prior quarter.
• Over the last five years, Return on Capital Employed for ONC reached as high as 10.46% in Q1 2026 and fell as low as 38.47% in Q1 2023.
• Historically, Return on Capital Employed has averaged 17.94% across 5 years, with a median of 20.04% in 2022.
• Across the five-year window, Return on Capital Employed slumped 2177 bps in 2022 and jumped 2727 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 34.51% in 2022, then climbed by 9 bps to 31.33% in 2023, then soared by 50 bps to 15.52% in 2024, then soared by 147 bps to 7.35% in 2025, then soared by 42 bps to 10.46% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 10.46% in Q1 2026, 7.35% in Q4 2025, and 3.97% in Q3 2025.